201 related articles for article (PubMed ID: 11350879)
41. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
42. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
43. Development of a delivery system for the continuous endogenous release of an anti-idiotypic antibody against ovarian carcinoma.
Hann E; Reinartz S; Clare SE; Passow S; Kissel T; Wagner U
Hybridoma (Larchmt); 2005 Jun; 24(3):133-40. PubMed ID: 15943560
[TBL] [Abstract][Full Text] [Related]
44. [Study of immunization protocol of ovarian carcinoma associated 6B11 anti-idiotypical minibody].
Zhu HL; Li Y; Chang XH; Cui H; Feng J; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):52-6. PubMed ID: 16635330
[TBL] [Abstract][Full Text] [Related]
45. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
46. The anti-idiotype vaccines for immunotherapy.
Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733
[TBL] [Abstract][Full Text] [Related]
47. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
Pfisterer J; du Bois A; Sehouli J; Loibl S; Reinartz S; Reuss A; Canzler U; Belau A; Jackisch C; Kimmig R; Wollschlaeger K; Heilmann V; Hilpert F
Ann Oncol; 2006 Oct; 17(10):1568-77. PubMed ID: 17005631
[TBL] [Abstract][Full Text] [Related]
48. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
[TBL] [Abstract][Full Text] [Related]
49. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
[TBL] [Abstract][Full Text] [Related]
50. [The induction of specific immunity to human ovarian carcinoma cells by anti-idiotypic antibodies].
Lu WY; Qian HN; Li WJ
Zhonghua Fu Chan Ke Za Zhi; 1994 Jan; 29(1):27-9, 60-1. PubMed ID: 8033621
[TBL] [Abstract][Full Text] [Related]
51. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
52. Appraisal of anti-idiotypic antibodies in the treatment of solid tumors in humans.
Euhus DM; Wong JH
Surg Gynecol Obstet; 1992 Jul; 175(1):89-96. PubMed ID: 1621207
[TBL] [Abstract][Full Text] [Related]
53. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
54. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
Buller RE; Shahin MS; Horowitz JA; Runnebaum IB; Mahavni V; Petrauskas S; Kreienberg R; Karlan B; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):567-72. PubMed ID: 12082456
[TBL] [Abstract][Full Text] [Related]
55. Monoclonal anti-idiotype antibody bearing the internal image of nasopharyngeal carcinoma associated antigen.
Li G; Hu J; Zhou G; Zhu J; Sun Q
Chin Med J (Engl); 2001 Sep; 114(9):962-6. PubMed ID: 11780392
[TBL] [Abstract][Full Text] [Related]
56. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
57. Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody.
Somasundaram R; Zaloudik J; Jacob L; Benden A; Sperlagh M; Hart E; Marks G; Kane M; Mastrangelo M; Herlyn D
J Immunol; 1995 Sep; 155(6):3253-61. PubMed ID: 7673738
[TBL] [Abstract][Full Text] [Related]
58. Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response.
Ma J; Zhou L; Wang D
Jpn J Cancer Res; 2002 Jan; 93(1):78-84. PubMed ID: 11802811
[TBL] [Abstract][Full Text] [Related]
59. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.
Moulton HM; Yoshihara PH; Mason DH; Iversen PL; Triozzi PL
Clin Cancer Res; 2002 Jul; 8(7):2044-51. PubMed ID: 12114402
[TBL] [Abstract][Full Text] [Related]
60. Biologic and immunologic therapies for ovarian cancer.
Berek JS; Schultes BC; Nicodemus CF
J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
